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Fredrik Wiklund, Sophie D Fosså, for the Scandinavian Prostate Cancer Group Study 7 and the Swedish Association for Urological Oncology 3
Summary
Background Several studies have shown the eﬃ  cacy of endocrine therapy in combination with radiotherapy in 
high-risk prostate cancer. To assess the eﬀ ect of radiotherapy, we did an open phase III study comparing endocrine 
therapy with and without local radiotherapy, followed by castration on progression.
Methods This randomised trial included men from 47 centres in Norway, Sweden, and Denmark. Between February, 
1996, and December, 2002, 875 patients with locally advanced prostate cancer (T3; 78%; PSA<70; N0; M0) were centrally 
randomly assigned by computer to endocrine treatment alone (3 months of total androgen blockade followed by 
continuous endocrine treatment using ﬂ utamide; 439 patients), or to the same endocrine treatment combined with 
radiotherapy (436 patients). The primary endpoint was prostate-cancer-speciﬁ c survival, and analysis was by intention 
to treat. This study is registered as an international standard randomised controlled trial, number ISRCTN01534787.
Findings After a median follow-up of 7·6 years, 79 men in the endocrine alone group and 37 men in the endocrine plus 
radiotherapy group had died of prostate cancer. The cumulative incidence at 10 years for prostate-cancer-speciﬁ c 
mortality was 23·9% in the endocrine alone group and 11·9% in the endocrine plus radiotherapy group (diﬀ erence 12·0%, 
95% CI 4·9–19·1%), for a relative risk of 0·44 (0·30–0·66). At 10 years, the cumulative incidence for overall mortality 
was 39·4% in the endocrine alone group and 29·6% in the endocrine plus radiotherapy group (diﬀ erence 9·8%, 
0·8–18·8%), for a relative risk of 0·68 (0·52–0·89). Cumulative incidence at 10 years for PSA recurrence was 
substantially higher in men in the endocrine-alone group (74·7% vs 25·9%, p<0·0001; HR 0·16; 0·12–0·20). After 
5 years, urinary, rectal, and sexual problems were slightly more frequent in the endocrine plus radiotherapy group.
Interpretation In patients with locally advanced or high-risk local prostate cancer, addition of local radiotherapy to 
endocrine treatment halved the 10-year prostate-cancer-speciﬁ c mortality, and substantially decreased overall mortality 
with fully acceptable risk of side-eﬀ ects compared with endocrine treatment alone. In the light of these data, endocrine 
treatment plus radiotherapy should be the new standard.
Funding Schering-Plough, Abbott Scandinavia, Nordic Cancer Union, Swedish Cancer Society (070604), Norwegian 
Cancer Society, Lions Cancer Foundation, and Umeå University.
Introduction
Hormone therapy alone or radiotherapy alone have for 
decades been acceptable treatments for locally advanced 
prostate cancer. The addition of hormonal therapy to 
radiation adds survival beneﬁ ts compared with radiation 
alone,1–5 but the eﬀ ect of this approach is still unclear.6 
Whether the beneﬁ ts of combining these treatment 
strategies are due to hormone-induced radiosensitisation 
or due to an eﬀ ect on micro-metastases remains to be 
proven. Despite an increase of local aggressive treatment 
in prostate cancer, and although more than 10 years has 
passed since the design of this study, the issue of whether 
local radiotherapy adds to hormonal treatment alone in 
locally advanced prostate cancer is still open.
After a hearing with the providers of the antiandrogen 
drugs ﬂ utamide and bicalutamide, presenting their latest 
data, the anti-androgen therapy was chosen in 1995, due to 
the early results showing similar eﬃ  cacy in non-metastatic 
prostate cancer and the decrease in side-eﬀ ects. The eﬀ ect 
of bicalutamide has been better documented than has 
ﬂ utamide, but to our knowledge no strong documentation 
has been provided that ﬂ utamide is less eﬀ ective. Both 
drugs have a similar mechanism of action. In the Swedish 
randomised POSAPROCA study with 468 patients 
with metastatic prostate cancer, ﬂ utamide 250 mg three 
times a day was compared with total androgen blockade, 
and results showed no diﬀ erence in overall survival at 
5-year follow-up. On progression, ﬂ utamide was supple-
mented with luteinising-hormone releasing hormone-
agonist (LHRH) as castration treatment (Jonas Hugosson, 
Gothen burg University, Sweden, personal communi-
cation).
The bicalutamide early prostate cancer programme 
shows that early antiandrogen treatment is better than 
deferred treatment in locally advanced prostate cancer 
(SPCG-6).7 The same programme showed that long-term 
bicalutamide in combination with radiation treatment 
improves outcome compared with radiation alone. Based 
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on the results from early prostate cancer trials,8 
antiandrogen treatment has become the preferred 
treatment in patients with non-metastatic locally 
advanced prostate cancer who are not suitable for 
curative treatment. However, antiandrogens are not 
recommended for treatment of early localised prostate 
cancer since survival beneﬁ t has not been shown.7–12
To assess the importance of local radiotherapy in 
patients with high-risk prostate cancer, in 1996 the 
Scandinavian Prostate Cancer Group and the Swedish 
Association for Urological Oncology started a phase III 
trial that explored the role of local radiotherapy in addition 
to endocrine treatment in patients with high-risk prostate 
cancer. The SPCG-7/SFUO 3 trial randomised patients to 
endocrine treatment alone or radiotherapy of the prostate 
together with endocrine treatment. After a median 
observation time of almost 8 years, we now present the 
results of the ﬁ rst analysis.
Methods
Patients
This trial included men from 47 centres in Norway, 
Sweden, and Denmark. Eligibility criteria were histo-
logical-proven prostate cancer in men younger than 76, 
who had a good performance status, a life expectancy of 
more than 10 years, and were categorised as clinical 
T1b–T2, G2–G3, or T3 (TNM-classiﬁ cation 1992), any 
WHO Grade 1–3. Participants had a prostate speciﬁ c 
antigen (PSA) of 70 ng/mL or less, and no evidence of 
metastases as determined by bone scanning and 
pulmonary radiography. Participants with a PSA of 
11 ng/mL or more had a pelvic lymph node dissection 
(fossa obturatoria); patients with nodal disease were not 
eligible for the trial. Ethics approval was granted by Umeå 
University, Medical Faculty Ethical Committee. All 
participants gave written informed consent before 
participation in the study.
Procedures
Patients were randomly assigned to receive either 
endocrine alone or endocrine plus radiotherapy, with 
stratiﬁ cation according to study centre, T stage, and 
grade. Randomisation was by computer with a block size 
of four through a telephone service at the Oncology 
Centre at Umeå University.
After randomisation, all patients were given endocrine 
treatment with total androgen blockade with an 
LHRH-agonist, leuprorelin (Procren depot; Abbott, 
3·75 mg a month or 11·25 mg every 3 months), for 
3 months and were simultaneously treated with 250 mg 
of an oral antiandrogen, ﬂ utamide (Eulexin, 
Schering-Plough) three times a day. After 3 months of 
total androgen blockade, patients continued using ﬂ uta-
mide until progression or death. After 3 months, patients 
in the endocrine plus radiotherapy group started 
radiotherapy. When antiandrogen treatment side-eﬀ ects 
were evident, ﬂ utamide was stopped and then reinstituted 
with stepwise increased dose to at least 500 mg. If this 
treatment failed, antiandrogen was changed to 
bicalutamide (150 mg once a day). 80% of all patients 
received breast irradiation to prevent gynecomastia.13
Initially, castration was recommended at time of 
appearance of clinical symptoms related to progression. 
No change of treatment was recommended in the event 
of PSA increase only. After the ﬁ rst publication of the 
SPCG-6 data in 2002,14 the addition of leuprorelin was 
880 assessed for eligibility
439 received endocrine
 treatment alone
436 received endocrine
 plus radiotherapy
5 did not meet 
 inclusion criteria
875 randomised between
 February, 1996, and
 December, 2002
 0 lost to follow-up  0 lost to follow-up
 439 analysed  436 analysed
Figure 1: Trial proﬁ le
Endocrine 
(N=439)
Endocrine plus 
radiotherapy (N=436)
Age in years, mean (SD) 66·2 (5·1) 65·7 (5·5)
Median PSA (IQR), ng/mL 16·0  (8·9–27·0) 16·0 (9·0–26·7)
Mean PSA, ng/mL 19·8 19·9
Tumour stage, number (%)
T1b 1 (0·2) 2 (0·5)
T1c 7 (1·6) 9 (2·1)
T2 83 (18·9) 86 (19·7)
T3 347 (79) 335 (76·8)
Unknown 1 (0·2) 4 (0·9)
WHO grade, number (%)
I 66 (15) 65 (14·9)
II 283 (64·5) 289 (66·3)
III 84 (19·1) 80 (18·3)
Unknown 6 (1·4) 2 (0·5)
Seminal vesicle involvement, 
number (%)
107 (24·4) 96 (22·0)
PSA level, number (%)
<4 ng/mL 26 (5·9) 22 (5·0)
4–10 ng/mL 104 (23·7) 110 (25·2)
10·1–20 ng/mL 132 (30·1) 132 (30·3)
20·1–30 ng/mL 90 (20·5) 85 (19·5)
>30 ng/mL 87 (19·8) 87 (20·0)
PSA=prostate speciﬁ c antigen.
Table 1: Baseline characteristics 
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allowed before clinical progress when the PSA level was 
more than 10 μg/mL.
A standard 3D conformal radiotherapy technique was 
applied with a prescribed central dose (of 50 Gy) to the 
prostate and the seminal vesicles. A sequential boost of 
at least 20 Gy was added to the prostate, which received a 
total dose of minimum 70 Gy. A margin of 20 mm (15 mm 
in posterior direction) was added. If optimum immobil-
isation could be achieved, the margins were reduced 
accordingly. A dose heterogeneity of 95–107% was 
allowed. To compensate for internal prostate movement 
and uncertainty in daily setup, a geometrical margin 
(2 cm) was established between the CT-veriﬁ ed prostate 
or seminal vesicles and the edge of the ﬁ eld. When 
invasion to the seminal vesicles was detected using 
palpation or TRUS-guided biopsy, 70 Gy was given. If 
more than half of the rectal cross-section received an 
accumulated dose higher than 50 Gy, the posterior 
margin was reduced. Pelvic lymph nodes were not 
intentionally irradiated, but some of the obturatorious 
nodes were included in the standard target volume.
The primary objective was to explore if addition of 
radiotherapy to endocrine treatment would improve 
cancer-speciﬁ c survival at 7 years compared with 
endocrine treatment alone. Secondary objectives were 
PSA recurrence (the time from randomisation to ﬁ rst 
occurrence of a PSA recurrence or death from prostate 
cancer), overall mortality (time from randomisation to 
death irrespective of cause), and quality of life.
The primary endpoint was prostate-cancer-speciﬁ c mor-
tality, deﬁ ned as the time from randomisation to death 
from prostate cancer or death from another cause with 
prostate cancer as a signiﬁ cantly contributing factor; deaths 
from other causes were treated as censoring events.
To ensure complete follow-up regarding survival 
status, all included patients were linked to nationwide 
population registries in Sweden, Norway, and Denmark 
(Feb 22, 2008). No patient was lost from follow-up due to 
emigration. For each patient that had died during 
follow-up, the responsible physician classiﬁ ed the cause 
of death into one of ﬁ ve categories: (1) death from 
prostate cancer; (2) death from another main cause with 
prostate cancer as a signiﬁ cantly contributing factor; 
(3) death from anticancer therapy; (4) death from another 
main cause without prostate cancer as a signiﬁ cantly 
contributing factor; and (5) death from unknown cause.
According to the protocol, PSA progression was deﬁ ned 
as an increase in PSA on two consecutive measurements 
with at least 1 month between them. Since new recom-
mendations deﬁ ne biochemical recurrence according to 
the 2006 American Society of Therapeutic Radiology 
(ASTRO) consensus, this deﬁ nition was changed 
accordingly and deﬁ ned as an increase of PSA of 2 ng/mL 
or more above nadir.15
Quality of life was assessed using the European 
Organization for Research and Treatment of Cancer 
(EORTC) QLQ-C30 questionnaire, with analysis done 
according to the EORTC recommendations.16 The 
questionnaires were ﬁ lled out before any treatment 
(baseline), at 3 and 6 months, and thereafter at 1, 2, 4, 8, 
and 10 years after start of treatment. We now report on 
quality of life information obtained at baseline and 
4 years after the start of treatment.
Sample size
Initially, we aimed to include 660 patients to provide a 
statistical power of 80% to detect an increased cause-speciﬁ c 
survival of 10% after 7 years of follow-up in the endocrine 
plus radiotherapy group compared with 65% in the 
endocrine group. In a blinded analysis of 716 enrolled 
patients by an independent Data Safety Monitoring 
Committee in February, 2002, the overall mortality was 
lower than anticipated. Therefore, the study steering board 
decided to extend the target sample size to 880 patients to 
achieve a total of 198 prostate cancer deaths after 7 years of 
follow-up. In February, 2008, after a median follow-up of 
7·6 years, the total number of prostate cancer deaths 
Endocrine Endocrine plus 
radiotherapy
p value
Bladder obstruction/sclerosis (yes*)
Baseline 14/428 (3%) 11/425 (3%) 0·686
60 months 6/269 (2%) 6/329 (2%) 0·775
Urethral stricture (yes*)
Baseline 1/428 (0%) 1/425 (0%) 1·000
60 months 0/269 (0%) 6/329 (2%) 0·035
Urinary frequency per 24 h (>10)
Baseline 59/424 (14%) 71/420 (17%) 0·253
60 months 47/265 (18%) 58/328 (18%) 1·000
Urgency (yes*)
Baseline 29/428 (7%) 29/425 (7%) 1·000
60 months 21/269 (8%) 47/329 (14%) 0·014
Incontinence, urinary (moderate or total†)
Baseline 2/428 (0%) 8/424 (2%) 0·063
60 months 7/269 (3%) 22/330 (7%) 0·022
Intestinal symptoms (moderate or severe‡)
Baseline 0/430 (0%) 1/425 (0%) 0·497
60 months 2/269 (1%) 10/331 (3%) 0·075
Erection (not enough or no erection)
Baseline 112/337 (33%) 112/314 (36%) 0·563
60 months 173/213 (81%) 236/266 (89%) 0·027
Sexual activity (last year or not last year)
Baseline 143/307 (47%) 152/288 (53%) 0·140
60 months 158/187 (84%) 194/227 (85%) 0·784
*Not graded. †Use diaper or total incontinence. ‡Diarrhoea requiring 
parasympatholytic drugs (>5 stools a day). Sometimes medication with imodium 
or pred-clysma; grade 2 toxicity. The following recorded symptoms were not 
signiﬁ cantly diﬀ erent between groups and are therefore not included in table 3: 
pain, analgesics, nausea/vomiting, hot ﬂ ushes, diarrhoea, macroscopic 
haematuria, and other symptoms.
Table 2: Proportion of patients reporting speciﬁ c levels of distress or 
dysfunction as reported by treating doctor at baseline and 5 years after 
treatment start
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was 116. Therefore, a new independent Data Safety 
Monitoring Committee was assigned to blindly explore the 
present power of the study. Because of a much higher than 
expected cancer-speciﬁ c survival in the complete cohort of 
patients (overall cancer-speciﬁ c survival was 90% after 
7 years compared with an assumed overall survival of 70%), 
the committee concluded that the study had more than 
adequate power to detect an increased cancer-speciﬁ c sur-
vival of 10% and recommended the study steering board to 
break the randomisation code and publish the results.
Statistical analysis
According to the study protocol, no interim analysis was 
done. All analyses were prespeciﬁ ed with an intention-
to-treat approach. To acknowledge the presence of 
competing risks, we calculated cumulative incidence for 
each endpoint.17 Gray’s test18 was used to test the hypothesis 
that there was no diﬀ erence between the treatment groups. 
Diﬀ erences in cumulative incidence (with 95% CIs) and 
relative risks (with 95% CIs) were used as measures of 
eﬀ ect for each endpoint. The relative risks were estimated 
using the Cox proportional-hazards model, and the 
cumulative incidence analysis was done using the 
“cmprsk” package developed by Gray.19 Eﬀ ect modiﬁ cation 
was tested by a Cox proportional-hazards model, which 
included an interaction term between subgroup category 
and treatment group. Subgroups assessed for eﬀ ect 
modiﬁ cation were age at diagnosis, PSA level at diagnosis, 
and T stage. Comparisons of quality of life scores within 
and between treatments groups were done with the 
Wilcoxon rank-sum and signed-rank test, respectively. 
Diﬀ erences between categorical variables were assessed 
by the χ² test. All reported p values are based on two-sided 
hypothesis with a p value of less than 0·05 considered to 
indicate statistical signiﬁ cance.
This study is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN01534787).
Role of the funding source
The Scandinavian Prostate Cancer Group, as the sponsor, 
has received unrestricted grants from: Schering-Plough 
and Abbott Scandinavia. Funding has also been provided 
from the Nordic Cancer Union, Swedish Cancer 
Society (070604), Norwegian Cancer Society, Lions Cancer 
Foundation, and Umeå University. Neither the sponsor nor 
any of the grants providers had any role in the design, data 
collection, data analysis, data interpretation, and writing of 
the report. Widmark as the corresponding author and the 
statistician (Wiklund) had full access to all data in the study 
and, together with the Study Board, had the ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between February, 1996, and December, 2002, 880 patients 
were randomised and 875 analysed (ﬁ gure 1). Baseline 
demographics and clinical characteristics were balanced 
between the groups (table 1). 35 (8%) men in the 
endocrine group and 58 (13·3%) men in the endocrine 
plus radiotherapy group had their dose of ﬂ utamide 
reduced, and 77 (17·5%) men in the endocrine group and 
88 (20·2%) in the endocrine plus radiotherapy group had 
their treatment changed to bicalutamide.
All patients in the radiotherapy group received 
curative radiotherapy with a prescribed dose to the 
planning target volume (PTV1 [prostate]) of 70·0 Gy or 
higher, 27 patients receiving 74 Gy or more. The median 
dose of PTV1 (prostate) was 70·0 Gy with an interquartile 
range of 69·5–70·6 Gy. No patients in the endocrine-
alone group received radiotherapy with curative intent, 
although six patients later received palliative 
radiotherapy due to local progression.
Follow-up started on date of randomisation and con-
cluded on Feb 22, 2008, or on the date of death. Every 
3 months for the ﬁ rst year and every 6 months thereafter, a 
clinical examination and assessment of PSA, liver function, 
and blood cell counts was done. Additionally, at each visit 
adverse events, assessed by the treating physician, were 
recorded according to a modiﬁ ed scale of the Radiation 
Therapy Oncology Group (table 2). Completeness of PSA 
follow-up was 95% in the endocrine group and 94% in the 
endocrine plus radiotherapy group. The study was not 
blinded and the physicians assessing the patients were 
aware of which study group the patient was allocated to.
With a median follow-up of 7·6 years (range 
0·2–11·9 years), 79 of the 439 (18·0%) patients in the 
Endocrine 
(N=439)
Endocrine plus 
radiotherapy 
(N=436)
Absolute risk 
reduction 
(95% CI)
Relative risk 
(95% CI)
p value
Disease-speciﬁ c mortality
Total number of events 79 37 ·· ·· ··
Mean follow-up, years 7·4 7·6 ·· ·· ··
7 years of follow-up, 
% (95% CI)
9·9 (7·1 to 12·8) 6·3 (3·9 to 8·6) 3·7 (0·0 to 7·4) ·· ··
10 years of follow-up, 
% (95% CI)
23·9 
(18·4 to 29·4)
11·9 
(7·4 to 16·5)
12·0 
(4·9 to 19·1)
0·44 
(0·30 to 0·66)
<0·001
Overall mortality
Total number of events 132 94 ·· ·· ··
Mean follow-up, years 7·4 7·6 ·· ·· ··
7 years of follow-up, 
% (95% CI)
20·1 
(16·2 to 23·9)
16·5 
(12·9 to 20·1)
3·6 (–1·7 to 8·8) ·· ··
10 years of follow-up, 
% (95% CI)
39·4 
(33·0 to 45·7)
29·6 
(23·3 to 36·0)
9·8 (0·8 to 18·8) 0·68 
(0·52 to 0·89)
0·004
PSA recurrence
Total number of events 285 77 ·· ·· ··
Mean follow-up, years 3·8 6·3 ·· ·· ··
7 years of follow-up, 
% (95% CI)
71·1 
(66·3 to 75·9)
17·6 
(13·6 to 21·5)
53·5 
(47·3 to 59·7)
·· ··
10 years of follow-up, 
% (95% CI)
74·7 
(69·6 to 79·8)
25·9 
(19·3 to 32·6)
48·8 
(40·4 to 57·2)
0·16 
(0·12 to 0·20)
<0·001
* Analysis of cumulative incidence was done with the cmprsk package developed by Gray.19 Relative risks were derived 
from Cox proportional-hazard models. Absolute risk reduction and relative risk are for endocrine plus radiotherapy 
treatment compared with endocrine treatment alone. Gray’s test was used for p values.
Table 3: Cumulative incidence of main endpoints and corresponding relative risks*
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endocrine-alone group and 37 of the 436 (8·5%) patients 
in the endocrine plus radiotherapy group died of prostate 
cancer. Of the 116 men that were classiﬁ ed as dead from 
prostate cancer, 28 (20 in the endocrine-alone group and 
eight in the endocrine plus radiotherapy group) were 
classiﬁ ed as dead from other causes but with prostate 
cancer substantially involved. The number of deaths 
from causes other than prostate cancer was 52 in the 
endocrine-alone group and 56 patients in the endocrine 
plus radiotherapy group. For two patients (one in each 
group) the cause of death could not be established.
The cumulative incidence at 7 years for cancer-speciﬁ c 
mortality was 9·9% (95% CI 7·1–12·8%) in the endocrine 
group and 6·3% (3·9–8·6%) in the endocrine plus 
radiotherapy group (diﬀ erence 3·7%, 0·0–7·4%). At 
10 years, the cumulative incidence for cancer-speciﬁ c 
mortality increased to 23·9% in the endocrine group and 
to 11·9% in the endocrine plus radiotherapy group with a 
signiﬁ cant diﬀ erence between treatment groups 
(diﬀ erence 12·0%, 4·9–19·1%). The relative risk of 
cancer-speciﬁ c death was 0·44 (0·30–0·66, p<0·0001) in 
favour of the endocrine plus radiotherapy treatment 
group (table 3, ﬁ gure 2).
As for cancer-speciﬁ c mortality, overall mortality was 
higher in the endocrine group than in the endocrine plus 
radiotherapy group. Radiotherapy treatment yielded an 
absolute improvement of 3·6% (95% CI –1·7 to 8·8%) at 
7 years and 9·8% (0·8–18·8%) at 10 years. The relative 
risk of overall death was 0·68 (0·52–0·89, p=0·004) in 
favour of the endocrine plus radiotherapy treatment 
group (table 3, ﬁ gure 2).
PSA recurrence revealed strikingly higher rates in the 
endocrine group than in the endocrine plus radiotherapy 
group. At 7 and 10 years, the cumulative incidence of PSA 
recurrence was 71·1% (95% CI 66·3–75·9%) and 74·7% 
(69·6–79·8%) in the endocrine group, and 17·6% 
(13·6–21·5%) and 25·9% (19·3–32·6%) in the endocrine 
plus radiotherapy group. The relative risk of PSA 
recurrence was 0·16 (0·12–0·20, p<0·0001) in favour of 
the endocrine plus radiotherapy treatment group (table 3, 
ﬁ gure 2).
No signiﬁ cant eﬀ ect modiﬁ cation of the combined 
treatment according to T stage, PSA level at diagnosis, or 
age at inclusion was seen for any of the endpoints. 
Subgroup analysis stratiﬁ ed by T stage, PSA level, and 
inclusion age uniformly revealed decreased 10-year 
cumulative incidence of prostate-cancer-speciﬁ c mortality 
in the radiotherapy group. In particular, this decrease was 
evident in patients with T1b–T2 tumours, where the mean 
absolute risk reduction was 16·0% (95% CI 3·7–28·2; 
ﬁ gure 3).
Table 2 presents the doctor-assessed moderate and 
severe side-eﬀ ects at 5-year follow-up compared with 
baseline. Signiﬁ cantly more patients in the endocrine plus 
radiotherapy group had urinary incontinence, urgency, 
urethral stricture, and erectile dysfunction. The diﬀ erence 
i n 
intestinal symptoms was not signiﬁ cant (p=0·075). 
18 serious adverse events were reported: diarrhoea (4), 
liver toxicity (6), photosensitivity (4), interstitial ﬁ brosis of 
the lung (1), thrombocytopenia (1), deep venous throm-
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Figure 2: Cumulative incidence of (A) PSA recurrence, (B) death from 
prostate cancer, and (C) death from any cause 
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bosis (1), and urinary retention due to carcinosarcoma in 
the prostate (1). Events were evenly distributed between 
the two groups (11 in the endocrine alone group and seven 
in the endocrine plus radiotherapy group).
The proportion of missing questionnaires at baseline 
and during follow-up was equally distributed between 
treatment groups. At the 4-year follow-up 340 of 399 (85%) 
men in the endocrine group and 359 of 401 (89%) men in 
the endocrine plus radiotherapy group returned the 
questionnaire (table 4). No signiﬁ cant diﬀ erence in global 
health and quality of life score was seen 4 years post-
treatment. 
Social function was the only function scale, whereas 
diarrhoea was the only symptom that diﬀ ered substantially 
between the two groups at 4 years (table 4). Moderate or 
severe diarrhoea at 4 years were reported by 32 of 
337 (9·5%) patients in the endocrine only group, whereas 
39 of 355 (11·6%) in endocrine plus radiotherapy group 
reported the same side-eﬀ ect (p=0·003). Emotional 
function was signiﬁ cantly improved at the 4-year 
follow-up (mean 85) compared with the baseline 
assessment (mean 82) in the endocrine plus radiotherapy 
group (p=0·006; table 4).
Dyspnoea and fatigue were the only symptoms on the 
QLQ-C30 questionnaire that increased signiﬁ cantly 
between baseline and 4-year follow-up in both groups 
(table 4). The most pronounced change was seen in 
dyspnoea, where the absolute increase between baseline 
and 4 years was 21% in the endocrine group and 24% in 
the endocrine plus radiotherapy group. However, 
dyspnoea and fatigue increased substantially in both 
groups between baseline and 3 months.
Discussion
The present study indicates a signiﬁ cant superiority of the 
endocrine plus radiotherapy treatment compared with 
endocrine treatment alone in patients with locally advanced 
prostate cancer. The endocrine treatment plus radiotherapy 
resulted in a substantial reduction in prostate cancer 
mortality. This signiﬁ cant diﬀ erence, which at 10 years 
reached 12%, also translated into improved diﬀ erence in 
overall survival (9·8%). 37 patients in the endocrine plus 
radiotherapy group died from prostate cancer compared 
with 79 patients in the endocrine alone group.
Several large randomised studies have shown that the 
combination of radiotherapy and androgen-deprivation 
improves outcome over radiotherapy alone in high-risk 
prostate cancer. Survival beneﬁ t depends on the duration 
of the hormonal treatment,2,20 and was also reported by 
the Early Prostate Cancer Programme using adjuvant 
antiandrogen treatment.8 In studies with androgen 
deprivation of short or intermediate duration (less than 
3 years), survival prolongation has only been reported in 
subgroups.3,21,22 In the present study, the survival at 10 years 
increased from 60·6% to 70·4% in favour of the endocrine 
plus radiotherapy treatment, and the improvement was 
achieved without excess long-term toxicity. These results 
clarify the importance of local radiotherapy treatment in 
high-risk patients with prostate cancer.
Recent reports suggest that the risk of cardiometabolic 
problems with long-term castration deprivation therapy 
could counteract the beneﬁ ts of hormonal therapy,23,24 
although this has also been questioned.25 Using anti-
androgens might be a way to avoid these diﬃ  culties and 
could reduce risk of osteoporosis, ﬂ ush, and impotence.
This study has a few limitations. In some parts of the 
world, medical or surgical castration is still the preferred 
treatment of locally advanced prostate cancer. Due to the 
pronounced side-eﬀ ects of surgical and medical castration, 
the role of monotherapy with oral antiandrogens has been 
Endocrine Endocrine plus 
radiotherapy
p (group)
Baseline 
(N=413)
4 year 
(N=340)
p 
(time)†
Baseline 
(N=423)
4 year 
(N=359)
p 
(time)†
Baseline 
(group)‡
4 year 
(group)§
Functioning scale QLQ-C30*
Physical function 98·0 96·0 <0·001 97·7 95·6 <0·001 0·666 0·305
Role function 87·0 81·0 <0·001 84·2 79·7 0·010 0·120 0·674
Emotional function 84·6 85·8 0·098 81·5 84·6 0·006 0·031 0·422
Cognitive function 88·1 82·1 <0·001 85·8 80·8 <0·001 0·033 0·362
Social function 88·0 80·7 <0·001 85·7 76·2 <0·001 0·092 0·010
Global health/
quality of life
78·4 76·1 0·189 77·5 73·1 0·005 0·661 0·059
Single symptom QLQ-C30¶
Fatigue 17·1 26·4 <0·001 20·6 27·9 <0·001 0·235 0·528
Nausea/vomiting 2·2 3·6 0·054 2·5 3·6 0·095 0·934 0·843
Pain 10·5 11·6 0·551 12·3 11·1 0·440 0·603 0·400
Dyspnoea 12·7 23·0 <0·001 13·0 25·5 <0·001 0·866 0·402
Insomnia 14·8 19·3 0·004 16·7 19·1 0·222 0·096 0·905
Appetite loss 4·0 4·4 0·469 5·0 5·9 0·628 0·114 0·228
Constipation 10·7 12·9 0·314 9·9 14·9 0·003 0·598 0·186
Diarrhoea 13·0 14·0 0·931 12·0 18·6 <0·001 0·314 0·003
Financial 
diﬃ  culties
5·5 5·8 0·538 5·8 7·4 0·135 0·859 0·319
*On function and global quality of life scales, higher scores indicate better function or better quality of life. 
†Comparison between baseline and 4 years within the diﬀ erent groups; Mann-Whitney test. ‡Comparison between 
endocrine and endocrine plus radiotherapy at baseline. §Comparison between endocrine and endocrine plus 
radiotherapy at the 4-year follow-up. ¶Higher scores indicate more severe symptoms.
Table 4: Quality of life scores (EORTC QLQ-C30) in endocrine group and endocrine plus radiotherapy group
T1b-T2 16·0 (3·7 to 28·2)
T3 10·6 (2·1 to 19·0)
PSA <20 ng/mL 72·2 (–1·8 to 16·2)
PSA >20 ng/mL 17·3 (6·0 to 28·5)
Age <67 years 9·8 (–1·1 to 20·7)
Age >67 years 12·9 (3·4 to 22·5)
All 12·0 (4·9 to 19·1)
  Mean (95% CI)
–5 0
Absolute risk reduction (%)
105 15 302520
Figure 3: Absolute risk reduction in 10-year cumulative incidence of 
prostate-cancer-speciﬁ c mortality in the endocrine plus radiotherapy group 
as compared to the endocrine alone group stratiﬁ ed by T stage, diagnostic 
PSA level, and age at start of treatment
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explored during the past two decades. In non-metastatic 
patients, no diﬀ erence in eﬃ  cacy and survival was seen 
between antiandrogens and medical castration with a 
median follow-up time of 6·3 years, and patients treated 
with antiandrogens had signiﬁ cantly fewer side-eﬀ ects 
than patients treated with castration.10 The Early Prostate 
Cancer Program showed that the use of antiandrogen 
reduced mortality in patients with locally advanced disease.8 
On the basis of these results, the use of non-steroidal 
antiandrogen therapy in M0 patients has been well 
established in clinical routine in Europe and is considered 
an alternative to castration according to the European 
Association of Urology guidelines. In the present study, 
the endocrine treatment was 3 months of total androgen 
blockade (LHRH plus antiandrogen) followed by 
non-steroidal antiandrogens. Castration treatment (total 
androgen blockade) was then reinstituted on PSA 
progression. In 1995, when our study was designed, the 
choice of antiandrogen was based on preliminary reports 
on outcomes comparable with that after castration, but less 
side-eﬀ ects.9 In the present study, we see no separation of 
survival curves until 4 years after randomisation, indicating 
the time taken for patients with locally advanced prostate 
cancer to develop hormone refractory disease (ﬁ gure 2). A 
further separation was seen after 7 years. We know of no 
comparative studies that have assessed radiation combined 
with antiandrogens or LHRH-agonists versus such 
endocrine treatment alone.
At the start of the present study, the standard radiation 
dose to the prostate was 70 Gy. With the invention of 
intensity-modulated and image-guided radiotherapy, 
radiation doses of 78 Gy or higher are now possible, and 
randomised studies have shown that biochemical 
relapse-free survival improves with high radiation doses. 
The clear overall survival beneﬁ t might increase further 
with the larger radiation doses now safely available.26–29
Since the combination of surgery and androgen 
deprivation has not shown any increased eﬃ  cacy over 
surgery alone, other mechanisms might be of importance 
for the radiation-induced improvement in local control 
and survival.30 Our results cannot directly be implemented 
for prostatectomy. Appropriate trials addressing this 
issue need to be undertaken.
The Scandinavian Prostate Cancer Group Study 4 
(SPCG-4) in localised disease reported a small absolute 
diﬀ erence in overall survival of 5% after a 12 year follow-up 
after radical prostatectomy when compared with deferred 
treatment.31 The present study shows a diﬀ erence of 9·8% 
at 10 years. The present study also shows a beneﬁ t in 
favour of the endocrine plus radiotherapy treatment in 
T2 tumours (absolute risk reduction 16%; ﬁ gure 3).
The beneﬁ ts of the endocrine therapy plus radiotherapy 
should be weighed against the expected adverse events. 
Our study shows a small but signiﬁ cant increase of 
moderate to severe late eﬀ ects related to urinary and 
sexual function. The patient-reported diarrhoea was 
signiﬁ cantly diﬀ erent at 4 years, which probably could 
explain the decreased social function in the radiotherapy 
group. This ﬁ nding has also been reported earlier.32,33 
Fatigue increased over time in both groups, consistent 
with a recent report.34 Patient acceptability was high (over 
85%), and the side-eﬀ ects of adding radiotherapy are 
acceptable in comparison to the survival gain achieved. 
Compared with endocrine treatment alone, the addition 
of deﬁ nitive prostate radiotherapy reduces the 10-year 
cancer-speciﬁ c and overall mortality by 12·0% and 9·8%, 
respectively, in non-metastatic prostate cancer patients 
with locally advanced tumours or tumours that are 
prostate-conﬁ ned but with aggressive histology. The quality 
of life and adverse eﬀ ect proﬁ le is acceptable. We there fore 
suggest that endocrine treatment plus radiotherapy 
should be the new standard of care for these patients.
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